Valuation: Jade Biosciences, Inc.

Market Cap 928M 829M 765M 694M 1.3B 88.08B 1.32B 9.21B 3.65B 46.15B 3.48B 3.41B 145B P/E 2026 *
-5x
P/E 2027 * -5.09x
Enterprise Value 582M 520M 480M 435M 814M 55.27B 828M 5.78B 2.29B 28.96B 2.18B 2.14B 91.29B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
99.21%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Jade Biosciences, Inc.

1 day-2.15%
1 week+8.31%
Current month+3.84%
1 month-0.82%
3 months-25.64%
6 months-42.13%
Current year-5.44%
1 week 13.54
Extreme 13.54
15.44
1 month 12.85
Extreme 12.8465
15.44
Current year 12.45
Extreme 12.45
28
1 year 8.36
Extreme 8.36
28
3 years 6.56
Extreme 6.565
28
5 years 6.56
Extreme 6.565
28
10 years 6.56
Extreme 6.565
28
Manager TitleAgeSince
Chief Executive Officer 50 2025-04-27
Director of Finance/CFO 38 2025-07-13
Chief Tech/Sci/R&D Officer - 2024-09-30
Director TitleAgeSince
Director/Board Member 50 2025-04-27
Director/Board Member 42 2025-04-27
Chairman 57 2025-04-27
Date Insider Type Main position Quantity % Market Cap. Importance
6/25/26 Free

Director

47,675 0.0966%
2/12/26 Free

General Counsel

196,875 0.4280%
2/12/26 Free

Chief Technology Officer

288,750 0.6277%
Change 5-day change 1-year change 3-year change Capi.($)
-2.15%+8.31%+46.93% - 928M
+2.41%+0.29%+42.02%+71.57% 64.69B
-0.15%+7.50%+11.01%+73.48% 54.78B
+0.57%+4.60%+10.07%+92.86% 53.49B
+0.37%+4.67%+27.03%+52.07% 45.98B
-1.21%+2.32%+21.80%+123.81% 42.94B
-0.37%+5.07%+249.91%+918.74% 40.08B
+0.05%+0.21%+18.26%+58.53% 33.52B
-0.38%+5.68%+36.43%+27.54% 23.67B
+1.19%-4.98%+29.01%-0.65% 23.97B
Average +0.03%+3.00%+49.25%+157.55% 38.4B
Weighted average by Cap. +0.38%+2.74%+47.57%+158.58%

Financials

2026 *2027 *
Net sales - -
Net income -204M -182M -168M -153M -286M -19.39B -290M -2.03B -803M -10.16B -766M -750M -32.02B -231M -206M -191M -173M -323M -21.94B -329M -2.29B -908M -11.5B -867M -849M -36.24B
Net Debt -346M -309M -285M -258M -483M -32.82B -491M -3.43B -1.36B -17.19B -1.3B -1.27B -54.21B -354M -316M -292M -264M -495M -33.58B -503M -3.51B -1.39B -17.59B -1.33B -1.3B -55.46B
Projected Income Statement - Annual - Jade Biosciences, Inc.
Logo Jade Biosciences, Inc.
Jade Biosciences, Inc. is a biotechnology company, which is focused on developing therapies for autoimmune diseases. The Company’s lead asset, JADE-001, is an investigational anti-A PRoliferation-Inducing Ligand (APRIL) monoclonal antibody for the treatment of Immunoglobulin A (IgA) nephropathy (IgAN), an autoimmune condition in which the kidney is damaged by pathogenic IgA containing immune complexes, leading to proteinuria and kidney function decline, and potentially progressing to end-stage kidney disease requiring dialysis or transplantation. Designed to block the APRIL protein, JADE-001 targets an underlying cause of IgAN, offering the potential to reduce pathogenic IgA levels, decrease proteinuria, and preserve kidney function over the long term. The Company’s pipeline also includes two undisclosed antibody discovery programs: JADE-002 and JADE-003, which are in preclinical development.
Employees
55
Date Price Change Volume
26-10-23 US$14.59 -2.15% 634,377
26-10-22 US$14.91 -1.45% 575,925
26-10-21 US$15.13 +1.82% 932,727
26-10-20 US$14.86 +7.45% 881,296
26-10-19 US$13.83 +2.67% 828,514
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
MarketScreener Ratings - Jade Biosciences, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
14.59USD
Average target price
50.12USD
Spread / Average Target
+243.56%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Jade Biosciences, Inc.
  1. Stock Market
  2. Stocks
  3. JBIO Stock